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ABSTRACT
Direct modulation of gene expression by targeting
oncogenic transcription factors is a new area of
research for cancer treatment. ERG, an ETS-family
transcription factor, is commonly over-expressed or
translocated in leukaemia and prostate carcinoma.
In this work, we selected the di-(thiophene-phenyl-
amidine) compound DB1255 as an ERG/DNA binding
inhibitor using a screening test of synthetic inhibi-
tors of the ERG/DNA interaction followed by elec-
trophoretic mobility shift assays (EMSA) validation.
Spectrometry, footprint and biosensor-surface
plasmon resonance analyses of the DB1255/DNA
interaction evidenced sequence selectivity and
groove binding as dimer. Additional EMSA
evidenced the precise DNA-binding sequence
required for optimal DB1255/DNA binding and thus
for an efficient ERG/DNA complex inhibition. We
further highlighted the structure activity relation-
ships from comparison with derivatives. In cellulo
luciferase assay confirmed this modulation both
with the constructed optimal sequences and the
Osteopontin promoter known to be regulated by
ERG and which ERG-binding site was protected
from DNaseI digestion on binding of DB1255.
These data showed for the first time the ERG/DNA
complex modulation, both in vitro and in cells, by a
heterocyclic diamidine that specifically targets a
portion of the ERG DNA recognition site.
INTRODUCTION
Development of therapeutic strategies for inhibiting tran-
scription is of major interest for modulating gene expres-
sion associated with various diseases. Transcription
factors are key regulators of gene expression, and their
deregulation, direct or indirect, is often associated with
oncogenesis, cancer development, invasiveness and metas-
tasis. However, in spite of their important cancer gener-
ation/progression roles, transcription factors have not
been extensively evaluated as targets for cancer treatment
strategies (1,2). As transcription factors are considered as
‘‘undruggable’’ targets because of difﬁculty to directly
modulate protein/DNA binding, most drug development
strategies act at the protein–protein interaction or protein
degradation levels. An example is the treatment of acute
promyelocytic leukaemia expressing the fusion protein
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using retinoid acid derivatives that target the DNA
binding activity of the RAR moiety (3). Alternatively,
other approaches were recently developed to target
protein–protein interactions using structurally speciﬁc
competitive drugs such as nutlin-3 that binds to MDM2
and avoids p53 degradation resulting from p53/MDM2
complex formation in numerous cancers (4). Another
approach was developed to target transcription factor
activities using compounds that block protein–DNA inter-
actions such as S3I-201 inhibiting Stat3/DNA binding (5),
the isoquinolone alkaloid compound berberine interfering
with TATA binding protein (6) or synthetic polyamides,
speciﬁcally designed for transcription factor/DNA modu-
lation through their sequence-selective binding to the
minor groove of the DNA helix (7). Such targeted tran-
scription factor/DNA complexes include NF-kB, EVI1
and ETS-1, leading to a decrease in the expression of
controlled genes (8–10). Non-speciﬁc DNA targeting is a
major limitation to the development of transcription
factor modulators as illustrated by echinomycin that
targets both HIF-1 and Myc/Max transcription factors
binding DNA (11). To bypass this drawback, identifying
new DNA-binding compounds and evaluating them for
DNA-binding selectivity using molecular studies are es-
sential to obtain more effective DNA sequence–speciﬁc
compounds.
With this aim, we focussed on the synthesis and DNA-
binding activities of heterocyclic diamidines for directly
targeting the DNA minor groove in a sequence-selective
manner. Previous work highlighted the ability of the
phenyl-furan-benzimidazole diamidine DB293 to inhibit
Pit-1 and Brn-3 transcription factor/DNA complex (12).
Because the used TranSignal protein/DNA array also
evidenced a much smaller effect on transcription factor
interactions to the ETS-binding site (EBS) (12), we then
focussed on the modulation of transcription factors that
interact with EBS. The minimal EBS core is the consensus
50-GGA(A/T)-30 known to be recognized by the ETS
family of transcription factors through their highly
conserved winged helix-turn-helix DNA-binding domain
(ETS-domain) (13,14). The ETS family is divided in 12
subgroups based on structural homologies, among which
ERG (ETS-related gene) is of particular interest for its
oncogenic function. ERG, together with FLI1 and FEV,
belongs to the ERG subgroup (15) on four recently
deﬁned subclasses based on their preferred ETS DNA–
binding sequences (16). The ETS proteins have regulatory
functions in embryonic development and physiological
processes including proliferation, apoptosis, vascu-
logenesis, differentiation and haematopoiesis (17).
However, aberrant expression could be associated with
cancer diseases. In the case of ERG, fusion of the
androgen-regulated gene TMPRSS2 to ERG sequences
induces an over-expression of ERG associated with
50% of prostate cancers with poor prognosis in >90%
of TMPRSS2-ERG-positive prostate cancers (18,19).
Other ETS fusion proteins (TMPRSS2-ETV1,
TMPRSS2-ETV4, TMPRSS2-FLI1) are also detected in
5–10% of prostate cancers (18,20). Moreover, over-
expression of ERG is observed in acute megakaryoblastic,
myeloblastic and lymphoblastic leukaemia, associated
with poor prognosis and frequent relapses (21–23).
Fusion proteins (FUS/TLS-ERG and ELF4-ERG) result-
ing from translocations have also been associated with
those leukaemia, resulting in aberrant expression of
ERG transcription factor (24,25). Furthermore, EWS-
FLI1 and EWS-ERG fusion proteins are commonly
observed in Ewing sarcoma (26,27). Despite their
frequent implication in cancer disease, those ETS tran-
scription factors are poorly studied in terms of inhibition
and are currently not used in targeted therapy. A few
studies investigated the inhibition of EWS-FLI1 in
Ewing sarcoma by using, for instance, the mimetic
peptide ESAP1 that directly binds EWS-FLI1 and alters
its oncogenic function, or YK-4-279 that blocks
EWS-FLI1 interaction with the RNA helicase A, leading
to the decrease in EWS-FLI1 transcriptional activity.
Moreover, YK-4-279 also targets ERG and ETV1 tran-
scription activities reducing motility and invasion of
cancer cells without targeting ETS/DNA binding
(28–30). Alternatively, the DNA minor groove alkylating
agent trabectedin (ET743) inhibits EWS-FLI1/DNA
binding and modulates a known EWS-FLI1 downstream
target in Ewing sarcoma cell lines (31). Using a high-
throughput screening strategy, the same group evidenced
similar in vitro and in vivo results with mithramycin (32).
Alternatively, another targeting approach was based on
the epigenetic modulation of ERG-positive tumors by
histone deacetylase inhibitors (33,34).
Our approach was to investigate ERG/DNA binding
inhibition using heterocyclic diamidine compounds that
target the minor groove of DNA. After selecting
DB1255 as the most active compound, its DNA binding
selectivity and that of ERG were studied to highlight their
respective optimal binding site. The efﬁciency of DB1255
in ERG/DNA binding inhibition was identiﬁed at the mo-
lecular and cellular levels. The results of this research
provide new directions in anticancer drug design.
MATERIAL AND METHODS
Chemicals and plasmids
All DB compounds (Table 1) were prepared using
methodologies previously reported (35,36) and prepared
as 5 or 10mM solutions in DMSO. CT-DNA was pur-




TCTCGAGCAAGAAGTTCGA) and all EBS-mutated
oligonucleotides were purchased from Eurogentec
(Belgium). The ERG-sensitive reporter plasmid Pye-LUC,
containing four copies of the artiﬁcial Py-enhancer-element
(Pye), has been described in Carrere et al. (37). pSG5,
pSG5-ERG, pSG5-FLI1, Pye-Luc, murine Osteopontin
(OPN) promoter reporter vectors OPN136/+77-Luc and
OPN136/+77mutant1-Luc were obtained as previously
described (38,39). pSG5-ETS-1 and -ETS-2 were generous
gifts from Dr Marc Aumercier (40), whereas pRSV-ERM,
PEA-3 and ETV1 were kind gifts from Dr Jean-Luc
Baert (41). pGL3-EBS-WT-1R, pGL3-EBS-WT-6R,
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pGL3-EBS-Em-6R and pGL3-EBS-Dm-6R reporter
plasmids were obtained on ligation between NheI and
XhoI restriction sites of an oligonucleotide with single
EBS-WT or 6-fold tandem repeat of EBS-WT, EBS-Em
or EBS-Dm elements, respectively, positioned 50 upstream
to the minimal SV40 promoter.
Electrophoretic mobility shift assay
All double-strand oligonucleotides were 50-radiolabelled
as described (12). The binding experiments were
performed as previously detailed (12), with some modiﬁ-
cations. Brieﬂy, 5 mg of HT29 nuclear extracts (Nuclear
extraction kit, Panomics, Fremont, CA, USA) or 2 ml of
ERG or other ETS proteins expressing reticulocyte lysates
(TNT-coupled reticulocyte lysate system, Promega,
Madison, WI, USA) were incubated for 20min in
binding buffer at 4C with the radiolabelled DNAs and
DB compounds at speciﬁed concentrations or 50-fold of
the same EBS oligonucleotide (speciﬁc) or EBS-m
(non-speciﬁc) as unlabelled competitors. Free DNA was
separated from protein–DNA complexes on a 6%
non-denaturating polyacrylamide gel under electrophor-
esis for 3 h 30min at 300V in 0.5 TBE buffer. Gel reve-
lations were performed using a Molecular Dynamics
STORM 860 and analysed with the ImageQuant-3.3
software.
DNase I footprint assay
pGL3-EBS-WT-1R, pGL3-EBS-WT-6R, pGL3-EBS-
Em-6R and pGL3-EBS-Dm-6R plasmids were digested
by ClaI and BglII restriction enzymes and radiolabelled
with [a-32P]dGTP at 30-termini as reported (42). The OPN
promoter DNA sequence was obtained by HindIII and
MluI restriction enzymes digestion of the OPN136/+77-
Luc vector. The generated DNA fragment was 30-end
radiolabelled using [a-32P]dCTP as speciﬁed previously.
DNA sequences were deduced from guanine positions
cleaved on DMS and piperidine treatment (G-track).
ELISA-derived protein/DNA binding inhibition assay
Streptavidin-coated 96-well plates (ThermoFicher) were
blocked with 200 ml of blocking solution Tris Buffer
Saline (TBS: 10mM Tris–HCl, pH 8, 150mM NaCl,
0.5% Tween and 5% BSA) for 1 h at room temperature
and 5.7 nM of biotinylated EBS-containing oligonucleo-
tide was immobilized per well for 1 h at room temperature.
After two washes for 5min with 200 ml of washing solution
(TBS-Tween 0.5%) at room temperature, ERG proteins
expressed from reticulocyte lysate system (Promega,
Madison, WI, USA) (2 ml of lysate previously diluted
to one-ﬁfth in sterile water) were incubated for 30min
at 4C with/without 5 mM of the indicated DB compounds
in binding buffer (10mM Tris–HCl, pH 7.5, 1mM EDTA,
1mM DTT, 75mM NaCl, 6% glycerol, 10 mg BSA).
After three washes, the ERG/DNA complex was
incubated with ERG antibody (sc-354, Santa Cruz
Biotechnology) in TBS-Tween 0.5%–0.5% BSA solution
1 h at room temperature. After three washes, ERG/DNA
complexes were detected by the incubation of the rabbit
horseradish peroxidase-conjugated secondary antibody
(Santa Cruz Biotechnology) in TBS-Tween 0.5%–BSA
0.5% solution for 1 h at room temperature. After two
washes of 5min with 200 ml of washing solution and
one with TBS alone, 100 ml of TMB (Promega, Madison,
WI, USA) was added and incubated for 15min at room
temperature. The reaction was stopped with 100 ml of
0.5M H2SO4, and the absorbance was measured at
450 nm on the microplate spectrometer (Molecular
Devices Versamax). All collected data was analysed
using SoftMax Pro software.
Table 1. Structure of the chemical compounds. The general sheme of
the compounds is presented on the top of the table. The external A1
and A2 and the central B1 and B2 cycles are as described in the
following table
aAll compounds are hydrochloride salts except DB1256, DB832, and
DB934, which are acetates.
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Spectrometric analysis of DNA binding
DNA melting temperature, UV/Visible spectroscopy and
circular dichroism experiments were performed as previ-
ously reported (43), with the following modiﬁcations. For
melting temperature studies (Tm), the indicated ratios
are expressed as drug/base pair. For UV spectroscopy,
DB1255 (20 mM) was incubated with increasing concentra-
tions of CT-DNA (0.1–200mM) or EBS-WT oligonucleo-
tide (0.1–50 mM). For circular dichroism spectrometry,
200mM (bp) of CT-DNA or EBS-WT oligonucleotide
was incubated with increasing concentrations of DB1255
from 1 to 50 mM and 0.01 to 10 mM, respectively. All three
experiments were performed in BPE buffer (6mM
Na2HPO4, 2mM Na2H2PO4, 1mM EDTA, pH 7).
Surface plasmon resonance analysis of the DNA binding
Surface plasmon resonance (SPR) measurements were
performed with a four-channel Biacore T200 optical
biosensor system (Biacore, GE Healthcare, Inc.).
50-biotin labelled hairpin oligonucleotides EBS-WT 50-G
CGTCGAACTTCCTGCTtctcAGCAGGAAGTTCGAC
GC-30 (the EBS-minimal sequence is underlined, loop in
lower case and stem in caps letters) or EBS-Dm 50-GCGT
CCCACTTCCTGCTtctcAGCAGGAAGTGGGACGC
-30 (mutated bases are in bold and italic letters) were
immobilized onto streptavidin-coated sensor chips
(Biacore SA) as previously described (44,45), with the dif-
ference that the compounds were injected in a solution
containing 10% DMSO to avoid drug precipitation in
the ﬂow cells at the highest drug concentrations.
Cell culture
Human cervical HeLa, colon HT29 and prostatic VCaP
carcinoma cells were grown at 37C under 5% CO2 in
Dulbecco’s modiﬁed Eagle’s medium (DMEM, Gibco)
supplemented with 10% foetal bovine serum, penicillin
(1000U/ml) and streptomycin (10 mg/ml).
Transient transfections
UsingHT29 cell line, 15 104 cells/well were cultured over-
night in 1ml of supplemented medium in 12-well plate.
Transfection was performed by adding a mixture of 3 ml
of lipofectamine 2000 (Invitrogen), 1.5mg of reporter
plasmid (pGL3-EBS-WT-6R, pGL3-EBS-Em-6R,
pGL3-EBS-Dm-6R or pGL3), 0.5 mg of pmaxGFP as a
normalising plasmid qsp 100 ml of OptiMEM medium
(Gibco, Invitrogen) previously incubated for 20min at
room temperature. After 6 h, the medium was changed by
complete medium supplemented, or not, with DB1255 at
the indicated concentrations, and cells were cultured for
24 h at 37C. The transfected cells were collected, rinsed
with PBS before lysis for 20min at 4C by lysis passive
buffer (Promega, Madison, Wisconsin, USA). After a 15-
min centrifugation at 13 000g, supernatants were collected.
Luciferase activity was quantiﬁed using Luciferase assay
system (Promega, Madison, Wisconsin, USA) according
to manual recommendations, whereas the ﬂuorescence
of GFP protein was detected using a 96-well
ﬂuorimeter (Mithras, Berthold) at excitation=485 nm and
emission=535 nm. For exogenous ERG expression in
HeLa cells, 2 105 cells/well were plated in 12-well plates
5 h before transfection using polyethylenimine
(Eurogentec) according to the manufacturer’s instructions.
DNA mixture included 500 ng of the indicated ﬁreﬂy
luciferase reporter gene with or without 200 ng of the ex-
pression vectors pSG5-ERG and 5 ng of a control plasmid
tk-luciferase (tk-Renilla, Promega). After 6 h, cells were
challenged with 2.5 mMof DB1255 for 20 h. Cells were har-
vested and luciferase activities were detected using the
Dual-Glo Luciferase Assay System (Promega). Luciferase
activity was measured on a luminometer (Berthold
Biolumat centro LB960). Fireﬂy luciferase values were
normalized to those of the control renilla luciferase.
Western blotting
Transfected cells were washed once with PBS and
incubated in ice-cold lysis buffer (50mM Tris–HCl,
10mM EDTA, 1% SDS, pH 8) for 2 h at 4C. After a
20-min centrifugation at 4C and 13 000g, the protein
extracts were collected, quantiﬁed (Bradford) and equal
amounts of proteins was denatured in loading buffer
(100mM Tris–HCl, pH 6.8, 200mM DTT, 4% SDS,
0.2% bromophenol blue and 20% glycerol) 3min at 90C
and loaded on SDS-PAGE. After gel electrophoresis, the
proteins were transferred onto a nitrocellulose membrane
(GE Healthcare, France), which was blocked for 1 h at
room temperature with TBS blocking solution (Tris–HCl
10mM pH 8, NaCl 150mM, Tween 0.5%) containing 5%
of BSA before immunodetection using polyclonal
anti-ERG antibody (sc-353, Santa Cruz, Biotechnology)
and revelation by ECL detection system (GE Healthcare)
using an HRP-conjugated secondary antibody (Santa
Cruz, Biotechnology). Anti-b-actin monoclonal antibody
(Sigma Aldrich) was used as an internal control.
RESULTS
Screening heterocyclic diamidines for inhibition of ERG/
DNA binding
Because previous researches highlighted some inhibitory
effects of DB293 on the ability of proteins to complex
with EBS sequence present on TranSignal protein/DNA
array, we ﬁrst investigated a series of transcription factors
belonging to the ETS family (ETS-1, ETS-2, ERG, FLI1,
ERM, PEA-3 and ETV1) for binding to this EBS-
containing sequence. Only ERG, and to a much lesser
extent FLI1, shows impressive band shift (data not
shown) and was therefore selected for inhibition with the
lead compound, DB293. The band shift was inhibited in a
similar dose–response manner using both ERG-expressing
reticulocyte lysate and HT29 nuclear extracts with full in-
hibition using 25 mM of DB293 (Supplementary Figure
S1A). In a DNaseI footprinting assay (Supplementary
Figure S1B), binding of DB293 at a site (grey box)
located on the 30-side of the minimal EBS (underlined in
black) was observed, as exempliﬁed by a strong negative
differential cleavage from 1.25mM. The minimal EBS site
was not sufﬁcient for ERG/DNA binding, which is known
to require speciﬁc 50 and 30 adjacent bases and the
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30 binding site of DB293 is in agreement with interference
of ERG/DNA binding.
We then challenged a new series of heterocyclic
diamidines of varied structure for ERG/DNA binding in-
hibition using an ELISA-derived Protein/DNA binding
inhibition assay (which we call here EPDBi). This
method can screen and quantify in one step using
96-well plates the inhibitory effect of a large series of com-
pounds for protein/DNA complex formation. A new
structural sub-type of diamidine compounds (Table 1)
gave promising inhibitory results (Figure 1). Structure/
activity analyses showed that di-thiophene derivatives
were more active than their di-furan or di-selenophene
counterparts. Among di-thiophenes, the di-thiophene-
phenyl-amidine DB1255 was a particularly efﬁcient inhibi-
tor with more than 90% of complex inhibited using 5 mM
of DB1255. At the same concentration, DB293 only
induced a 20% inhibition. Such relative inhibition efﬁ-
ciency was conﬁrmed using EMSA (Figure 2). Results
for ERG/DNA binding inhibition using EMSA were con-
sistent with those resulting from EDPBi assay where the
more efﬁcient competitors present two thiophenes as
central rings rather than furans or selenophenes. In the
di-thiophene series, the substitution of the di-phenyl by
di-pyridine (DB1247) or di-benzimidazole (DB1974)
heterocycles decreases the inhibition efﬁciency by only
40–60%. In conclusion, the DB1255 is selected as the
best inhibitor of the ERG/DNA binding. The protein/
DNA complex obtained with HT-29 nuclear extracts
was also inhibited on addition of increasing concentra-
tions of DB1255 (Figure S2).
DNA-binding properties of DB1255 and derivatives
DB1255 was selected for DNA binding studies using UV–
visible spectrometry, DNA melting temperature studies
and circular dichroism analysis of the mode of binding.
First, interaction of DB1255 with DNA was analysed
using spectroscopic analyses in the presence of EBS oligo-
nucleotide (EBS-WT) or CT-DNA (Figure 3 and
Supplementary Figure S3). The variation of the DNA
melting temperature indicates strong binding of DB1255
to the EBS-containing oligonucleotide, even at low drug/
DNA ratio (Figure 3A). UV/visible absorbance spectros-
copy evidenced hypochromic effects at low concentration
(0–4mM) of EBS-WT oligonucleotide (high drug/DNA
ratios) that is probably due to stacking of the compound
outside of the double helix. The spectra then evidenced
bathochromic and hyperchromic effects from 4 to 50 mM
with an isosbestic point at 460 nm that argues for a
stronger, single binding mode at the lower drug/DNA
ratios (Figure 3B). Circular dichroism spectrometry was
then performed to get an insight in the orientation of the
compound relatively to the DNA helix (groove binding or
intercalation) on addition of increasing concentrations of
DB1255. In the presence of DB1255 (Figure 3C), the
biphasic intrinsic CD signal is modiﬁed with the appear-
ance of a strong bisignate CD around 420 nm that argues
for a groove binding interaction of DB1255 and is con-
sistent with dimer binding to the EBS-containing oligo-
nucleotide (46). Similar conclusions could be obtained
on binding to CT-DNA (Figure S3).
The precise binding localization of DB1255 or deriva-
tives relative to the EBS site was determined using DNase
I footprinting assays as described previously for the
DB293 (Figure 4). For this purpose, we used the ClaI-
BglII DNA fragment containing the 6-fold repeated EBS
site from pGL3-EBS-WT-6R reporter vector. The
radiolabelled DNA was incubated with increasing concen-
trations of the various selected compounds before DNase
I mild digestion. The densitometric analyses were per-
formed for each gel. A representative gel is presented in
Figure 4 using the active compounds DB1255 and DB1998
for comparison with the inactive DB1974 or DB1975. The
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Figure 1. EPDBi for screening the ERG/EBS-WT binding inhibitors. EPDBi was performed on streptavidin-coated plates in which biotinylated
EBS-WT oligonucleotides were ﬁxed. ERG proteins were added together with the indicated DB compounds at 5 mM. Control corresponds to 100%
of ERG/DNA complex. EBS-WT DNA-binding speciﬁcity was validated by addition of 50-fold excess of EBS-WT (50 S) or non-speciﬁc oligo-
nucleotide (50 NS) in the binding buffer. Results are means±s.e.m. from two experiments both performed in triplicate.
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encompasses the 50-gAAGTTc site. The other compounds
that appeared to be less active from EPDBi (Figure 1)
were less selective or bound with lower afﬁnity to the
same portion of the DNA (Supplementary Figure S4).
Such binding only partially covers (underlined) the EBS
minimal binding site 50-GGAA, but also spans the import-
ant EBS binding sequence, 50-GTT, located 30 after it. In
conclusion, active compounds determined by EPDBi
showed an excellent DNA-binding recognition and
afﬁnity for the EBS binding site.
A B
C D
Figure 2. Validation of the ERG/EBS complex inhibition by the evaluated diamidine compounds. EMSA was performed with the EBS-WT
radiolabelled oligonucleotide incubated with ERG protein expressed in reticulocyte lysate systems or empty lysate made with the equivalent
empty vector, in the presence of thiophene (A), selenophene or furan (B–D) derivatives. Bound ERG/EBS-WT complexes (b, indicated by a
black arrow) were competed with increasing concentration of DB compounds (mM) and separated to free EBS-WT oligonucleotide (f, indicated
by black arrow) by electrophoresis migration. DNA binding speciﬁcity was determined by addition of 50-fold excess of the speciﬁc unlabelled
EBS-WT (50 S) or a non-speciﬁc unlabelled oligonucleotide EBSm (50 NS).
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Looking for DB1255 and ERG optimal binding sites
To get an insight in the precise bases that are crucial for
the DNA interaction, DNA binding capacity of the
selected compound DB1255 was evaluated in terms of
sequence selectivity using a DNase I footprint assay on
DNA fragments containing the wild-type EBS sequence
or EBS mutated at one position per experiment to get
information with all four nucleotides options at each pos-
ition. All nucleotides from positions 1 to+7 relative to
the minimal EBS site G1G0A+1A+2 were mutated and
evaluated for DB1255 binding selectivity (Figure 5A and
B). Radiolabelled DNA contained the three mutated EBS
surrounded with two wild-type EBS. At the external pos-
itions 1, 0 and+7, no major changes in the differential
cleavages from densitometric analyses were observed
whatever the nature of the nucleotide at those positions
suggesting that DB1255 has no selective binding to those
bases (Figure S5). By contrast, mutations in central pos-
itions from +1 to +5 affected (decreased or abolished)
DB1255 binding. Globally, DNase I footprinting data
demonstrate the importance of the A+1, A+2, T+4 and
T+5 bases for DB1255 selective binding to DNA.
Mutations at position +3 and +6, however, affected the
compound binding to a lesser extent (Figure S5). Values
from the densitometric analyses were used to deduce the
A B
Figure 4. Sequence selectivity of diphenyl di-thiophene diamidine compounds. (A) DNase I footprint assays showed the interaction sequences of the
DB compounds. The radiolabelled DNA fragment containing the six repeats of the EBS-WT sequence was incubated with the indicated concen-
trations of compounds (mM) and submitting to electrophoresis migration. The track labelled ‘‘G’’ is as in Supplementary Figure S1.
(B) Densitometric analysis derived from the gel and protected sites observed are indicated by black boxes.
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Figure 3. DNA-binding characteristics of the selected compound
DB1255. (A) Temperature melting assay of the EBS-WT oligonucleo-
tide in presence of the DB1255. Tm values were obtained from
the equation: DTm=(Tm(drug/DNA) – Tm(DNA)). (B) UV-spectroscopy
properties of the complex DB1255/DNA was observed using a
ﬁxed concentration of DB1255 and increasing concentrations of
EBS-WT oligonucleotide. (C) Circular dichroı¨sm properties
of EBS-WT oligonucleotide in presence of increasing concentrations
of DB1255. Major changes in spectra (B and C) were indicated
by black arrows.
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predicted logo of the frequencies of DNA recognition with
0.8mM of DB1255 using each single base pair mutation
(Figure 5C).
In parallel, the DNA binding selectivity of the ERG
transcription factor was evaluated in EMSA using 50-end
labelled oligonucleotides containing the EBS-WT
sequence or mutants at each single position from 5 to
+7 as indicated in Figure 5D and Supplementary
Figure S6. Globally, the mutations affecting the EBS
minimal site abolish the ERG binding as expected. In
addition, the same mutations at positions 2 (A!C) or
4 (G!A) and to a lesser extent +5 (T!G) increases
ERG/DNA binding intensity. For the surrounding pos-
itions 3, +3 and +4 the relative percentage of ERG/
DNA binding decreased relatively to EBS-WT suggesting
their relevance for the ERG/DNA binding. By contrast,
changing bases at the most external positions 5,+6 and
+7 did not signiﬁcantly modify ERG/DNA binding pro-
pensity. From those data, the predicted logo for ERG/
DNA binding selectivity is presented in Figure 5F. For
each mutated sequence that could form ERG/DNA
complexes (mutations 3A, all mutated points at positions
+5 to +7), we evaluated the propensity of DB1255 at a
ﬁxed concentration (1 mM) to inhibit ERG/DNA binding.
A strong decrease of the inhibition potency is observed as
expected for all three mutations (A, C and G) at +5
position (Figure 6A). This result is in agreement with
the consensus DNA binding site for DB1255 showing
that the presence of a T+5 is essential for the binding
(Figure 5) as well as for the ERG/DNA complex inhib-
ition (Figure 6A). In conclusion, comparison of DB1255
and ERG consensus binding sites exempliﬁes the necessity
of the presence of a common 50-AA(G/N)T-30 site that
encompasses the minimal EBS for optimal DB1255 inter-
action and for best ERG/DNA complex inhibition.
To evaluate the inhibition of ERG/DNA binding in
cells using luciferase assays, we selected from previous
analyses the ERG/DNA binding mutated sequences
(EBS-Em) and the DB1255/DNA binding mutated sites
(EBS-Dm) as being 50-GGAA! 50CCAA and 50-GGAA
GTTCGA! 50-GGAAGTGGGA, respectively (mutated
bases are underlined). The efﬁciency for binding of
DB1255 (Figure 6B) and other derivatives (data not
shown) to EBS-Em but not EBS-Dm sites was conﬁrmed
from comparison with the EBS-WT sites using DNaseI
footprinting assays on 6-fold repeated sequences
generated from the pGL3-EBS-6R, pGL3-EBS-Em-6R
and pGL3-EBS-Dm-6R reporter vectors as described in
the Materials and Methods section. As expected, inactive
compounds such as DB1974 and DB1975 did not present
any footprint on the three DNA fragments (data not
shown), whereas the active compounds DB1255 and
DB1998, and to a lesser extent DB1357 and DB1578
(Figure 6B and data not shown), displayed huge footprints
characterized by negative differential cleavages for
EBS-WT and EBS-Em but not for EBS-Dm sequences.
To get more quantitative analysis of the sequence
binding and selectivity of DB1255 on EBS-WT, SPR ex-
periments were conducted with DNA hairpin duplexes
containing EBS-WT or EBS-Dm sequences (Figure 6C).
Because of the poor solubility of DB1255, the experiments
were performed in a buffer containing 10% DMSO during
the whole experimental process. The impact of DMSO in
this context was evaluated using the DB1998 derivative,
which is more water soluble. The equilibrium and kinetic
constants obtained in the presence of 10% DMSO
(Figure S7) and in low concentrations of DMSO (data
not shown) were roughly the same and any correction is
less than experimental error. The sensorgrams for DB1998
(Figure S7A) showed fast kinetics of association and dis-
sociation, whereas that for DB1255 presented slower as-
sociation/dissociation rates, suggesting better binding
kinetics for DB1255 over DB1998. The steady state RU
values were plotted against Cf (free compound concentra-
tion, in M) and ﬁtted to a single or two sites model
(Figures 6D and S7B) and showed that both DB1255
and DB1998 present similar equilibrium constants for
EBS-WT but different ones for EBS-Dm sequence. Both
compounds have a single strong binding site for the WT
sequence (K1), with a second site that is 100–200 times
weaker (K2). The binding of DB1255 to the EBS-Dm
sequence is much weaker than that to EBS-WT, suggest-
ing that such mutations strongly affect the DNA binding
propensity of DB1255 as also observed earlier using
DNase I footprinting assays (Figure 6B). By contrast,
DB1998 binds strongly to EBS-Dm sequence, and K1 is
only reduced by a factor of 5 compared with EBS-WT,
suggesting lower binding selectivity (Figure S7B).
Therefore DB1255 appears to be the most interesting com-
pounds in this series and was therefore retained for further
cellular experiments. As part of our sequence validation,
we ﬁnally showed that the ERG protein binds to EBS-WT
and EBS-Dm, but not EBS-Em oligonucleotide (data not
shown), which conﬁrms the above data showing that the
two guanines at positions 1 and 0 are essential for the
ERG binding but not the bases at positions +5 and+6.
In competition studies, ERG binding to DNA is abolished
by increasing concentrations of DB1255 for the EBS-WT
sequence but not for the EBS-Dm sequences (Figure 6E).
Thus, those three sequences could be used for luciferase
assays.
Modulation of the ERG/EBS complex inhibition in cellulo
This experiment was performed in HT29 cell line, which
expresses the ERG transcription factor as visualized by a
Western blot (Supplementary Figure S8A). The cell
uptake and nuclear localization of DB1255 was evidenced
using ﬂuorescence microscopy based on DB1255 intrinsic
ﬂuorescence properties in comparison with the cytoplas-
mic localization of MitoFluor Red (a mitochondrial
tracer) (Supplementary Figure S8B). Such nuclear
localization is in agreement with genomic DNA as a
target for DB1255. Therefore, the luciferase assays were
performed in cells transfected with pGL3-EBS-WT-6R,
pGL3-EBS-Em-6R and pGL3-EBS-Dm-6R for 6 h
before the addition of DB1255 from 1 to 5 mM during
24 h, conditions for which DB1255 is not cytotoxic
(Figure S8C). After normalization relatively to GFP ex-
pression and empty vectors, we evidenced relative
ERG-dependent transactivation using EBS-WT and
EBS-Dm but not EBS-Em element, highlighting the
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Figure 5. Sequence selectivity of ERG and DB1255 DNA binding. (A) Sequence selectivity of the DB1255/DNA interaction. DNase I footprint
assays were performed with a DNA fragment containing three EBS sequences mutated at the indicated positions (positions 1 to +7, DNase I
footprint gels and densitometric analyses for the position 1 and 0 and position +3 to +7 are presented in Figure S5A). For each mutation
incubation with DB1255 at the indicated concentrations (mM) revealed protected sites of DB1255 interaction. The track labelled ‘‘G’’ is as in
Figure S1. (B) Densitometric analyses derived from the gels and EBS-WT (WT) sequence or EBS-mutated sequence are indicated by black boxes or a
grey boxes, respectively. (C) The logos were drawn using enoLOGOS (47), where the size of the letter is directly proportional to the binding afﬁnity
at 0.8 mM of the compound resulting for densitometric analysis (data shown in Figure S5B). (D) Sequence selectivity of the ERG binding to the
EBS-WT sequence. ERG binding sequence selectivity are observed by EMSA using radiolabelled EBS oligonucleotide WT (EBS WT) or mutated
(EBS mXN) at the indicated position (position X of base N) incubated with ERG protein expressed in reticulocyte lysate system or empty lysate.
EBS sequences with mutated positions from 5 to+7 were evaluated but only the EMSA with mutated positions+3 to+7 are shown here (EMSAs
of mutated position 5 to +2 are shown in Figure S6A). (E) Representation of the percentage of ERG/DNA complex derived from the gel
quantiﬁcation as means±s.e.m. relatively to EBS-WT. (F) The logos were drawn as above (full data presented in Figure S6B).
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crucial role of the GG bases of the EBS site that are
mutated in EBS-Em sequences (Figure 7A). In the
presence of increasing concentrations of DB1255, the
ERG-mediated transactivation at EBS-WT sites decreased
in a dose-dependent manner, consistent with the inhibition
of ERG/DNA binding observed in vitro in EMSA
(Figure 6E). No inhibitory effect is obtained using
EBS-Dm-containing reporter vector in agreement with
previous EMSA analyses (Figure 6E).
To conﬁrm this modulation we ﬁnally evaluated the
competitive activity of DB1255 on promoters that have
been described to be regulated by ERG protein such as
the OPN promoter (39). The DNA recognition of DB1255
at the EBS site was addressed using DNaseI footprinting
assays (Figure S9). The luciferase assay was performed in
HeLa cells as described previously (39). Because HeLa
cells do not express ERG protein, those cells were
co-transfected with the ERG-expressing vector or empty
vector as control (Figure 7B, bottom panel). The
pGL3-EBS-WT-6R (EBS-WT-Luc) previously evaluated
in HT-29 cells and the reference polyomavirus enhancer
(Pye) were ﬁrst evaluated from comparison with the
control to validate the model in HeLa cell line. An inhib-
ition of the ERG-mediated transactivation by DB1255
was obtained for both EBS-WT and Pye models. Such
inhibition could not be attributed to a decrease of the
transcription of ERG-expressing vector itself as visualized
in the embedded Western blot panel from comparison
with actin expression. Moreover, DB1255 also inhibits
ERG-mediated transactivation from the OPN promoter
(OPN136/+77-Luc) in a manner that is dependent on the
presence of the ERG-binding site because no signiﬁcant
effect is obtained using the sequence mutated at the
EBS at position 119 to 115 (50-GGAGGAAG
mutated to 50-GGTAAAAG in OPN136/+77 Mutant1-Luc)
(Figure 7B). Both luciferase assays bring out the inhibi-
tory effect of DB1255 on ERG/DNA binding in cells.
DISCUSSION
Transcriptional modulation of oncogenic transcription
factors is a new and promising area to develop targeted
therapies, particularly in cancer. Despite the difﬁculty to
target this class of proteins, many groups have investigated
their inhibition by using several approaches. One method
under development consists of targeting the protein–DNA
binding interaction using small DNA-binding compounds.
A B
C D E
Figure 6. Speciﬁcity of ERG/DNA and DB/DNA binding on mutated on EBS sequences or on DB binding sequences. (A) ERG/DNA binding
inhibition depending on mutated EBS sequences. The capacity of a ﬁxed concentration of DB1255 (1 mM) to inhibit ERG/DNA binding was
evaluated by EMSAs on mutated EBS sequences when a binding was possible. Binding complexes were quantiﬁed and expressed as following.
ERG/DNA binding inhibition by DB1255 with mutated EBS were measured as a percentage of the inhibition obtained with EBS-WT. ERG/DNA
binding inhibition by DB1255 obtained with EBS-WT sequence was scaled up to 1 and the percentage of inhibition with mutated EBS relative to
EBS-WT were plotted as fold-reduction of 1255 inhibition capacity. (B) Densitometric analysis of DB/DNA interaction derived from a DNase I
footprint (gels not shown). DNase I footprint assays were performed with DNA fragments containing six repeats of EBS-WT, EBS-Em (mutated on
the EBS element) or EBS-Dm (mutated on the compound site interaction) and compounds at the indicated concentrations. (C) SPR Sensorgrams for
DB1255 on the EBS-WT (left panel) or EBS-Dm (right panel) hairpin oligonucleotides. (D) Fitting analysis of SPR sensorgrams. RU values from the
steady-state region of SPR sensorgrams are plotted against free DB1255 concentration (M). The corresponding K1 and K2 values are calculated from
one or two site(s) ﬁtting models for EBS-Dm (Red) and EBS-WT (Blue) sequences. (E) ERG/EBS-WT and ERG/EBS-Dm binding modulation by
DB1255. Quantiﬁcation of the percentage of ERG/DNA complex formation was performed from EMSA gels (not shown).
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Such compounds speciﬁcally interact with the same DNA
site and consequently decrease the transcription factor/
DNA complexes leading to the diminution of gene tran-
scription. By using this competition approach of
transcription factor inhibition, we ﬁrst showed the possi-
bility of this inhibition concept using the heterocyclic
diamidine DB293, which targets Pit-1 and Brn-3 (12).
In that project, we showed that if compound binding to a
sequence (ATGA) common to that bound by a transcrip-
tion factor was important, it does not mean that all tran-
scription factors containing that sequence would be
affected. Indeed, the IRF-1 transcription factor consensus
interaction site also contains an ATGA sequence, but that
complex was not affected by the presence of DB293.
This result shows that the mode of binding of each tran-
scription factor needs to be taken into account in inhibition
design. Based on previous data using TranSignal Protein/
DNA arrays (12), we focussed here on the ERG transcrip-
tion factor and showed that the inhibition of ERG binding
to the DNA is obtained through the recognition of a
sequence that partially spans the minimal ERG-binding
site. It is known that the binding of the ETS-domain to
DNA requires direct recognition of conserved arginine
residues with the core 50-GGA(A/T)-30 in the major
groove as well as contacts with the phosphate backbone
within the minor groove at bases ﬂanking the minimal
50-GGA(A/T)-30 core (48). Thus, targeting one portion of
the EBS consensus may be sufﬁcient to impede ERG/DNA
binding. This is what we observed here using DB1255
and related derivatives. In terms of structure/activity rela-
tionships, changing di-thiophene rings in DB1255 for
di-furans or di-selenophenes abolishes sequence-selectivity
and the ERG/DNA binding inhibitory effect.
Among the di-thiophene series in which the di-phenyl
rings of DB1255 were changed for di-benzimidazole or in
which di-methyl-thiophene or di-thiazole substituted the
di-thiophen central rings, DB1255 remains the most
active. Such modiﬁcations may increase the stearic hin-
drance relative to DB1255, thus leading to the loss of
DNA recognition. Sulphur atoms are less electronegative
than oxygen atoms and develop weaker hydrogen bonding
but present better stacking properties than furan groups.
However, the size of the sulphur atoms is larger than that
of oxygen (but smaller than selenium atoms) and this can
increase the C-S-C bond angle of the thiophene rings of
DB1255 in comparison with the C-O-C angle in furan
rings (DB914). The selenium atoms may induce a much
larger angle that is no longer compatible with proper
DNA binding (DB1282). The optimal recognition seems
to require a balance between thiophene properties and the
curvature of this type of molecule for matching the minor
groove of the double helix of DNA. The different capacity
of inhibition was conﬁrmed by an EMSA assay (Figure 2)
where the more active compounds detected in the EDPBi
assay decrease the ERG/DNA complex in contrast with
the inactive compounds. As observed for DB293, the in-
hibition potency of active compounds strictly correlates
with their ability to partially cover the EBS minimal
50GGA(A/T) and to span the 50-GTT sequence located
30 to the minimal EBS sequence (Figure 4). The active
di-thiophene heterocyclic diamidine compounds inhibit
ERG/DNA complex formation through DNA interaction
on one portion of the EBS, leading to the destabilization
of ERG/DNA binding. As DB1255 is clearly the best
ERG/DNA complex inhibitor, we focused on that
A
B
Figure 7. In cellulo inhibition of the ERG/DNA complex by DB1255.
(A) Modulation of the ERG/DNA transcriptional activity on a 6-fold
repeated EBS-containing reporter vector. HT29 cells transfected with
luciferase vector with or without 6 repeat of the EBS-WT, EBS-Em or
EBS-Dm elements (point mutations indicated with arrow heads)
located upstream the cDNA of the luciferase (luc) gene, as indicated,
were incubated with increasing concentrations of DB1255 (24 h). The
fold-activation values correspond to the normalized luciferase activity
in comparison with cells transfected with empty vector. Results are
means±s.e.m. from three independent experiments performed in trip-
licate. Statistical analyses were performed using analysis of variance
test. (B) In cellulo inhibition of the transcriptional activity of
ERG-target gene promoter by the DB1255 compound on the OPN
promoter. Transfections were performed in HeLa cells using
ERG-expressing vector or empty control vector. For transcriptional
modulation, different reporter vectors were used: pGL3-Luc as empty
reporter, Pye-Luc as the reference of polyomavirus enhancer,
EBS-WT-Luc similar to pGL3-EBS-WT-6R, OPN136/+77-Luc as the
OPN promoter and OPN136/+77 Mutant1-Luc containing the OPN
promoter mutated on EBS. After transfection, HeLa cells were
treated or not with DB1255 (2.5 mM, 24 h). ERG and b-actin expres-
sions were detected by Western blotting (bottom and embedded
panels). Results are means ± s.e.m. from at least two experiments.
Statistical signiﬁcance was determined using one-way analysis of
variance, followed by Bonferroni’s multiple comparison post test.
*P< 0.05, **P< 0.01, ***P< 0.001, ns, non-speciﬁc (P> 0.05).
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compound for ﬁne analysis of sequence and cellular val-
idation. As usual for this class of compound, DB1255 is a
(minor) groove DNA binder as evidenced using both
non-speciﬁc CT-DNA and a sequence-speciﬁc EBS-
containing oligonucleotide (Figures 3 and
Supplementary Figure S3). The strong bisignate CD
spectra observed for this compound suggest a groove
interaction as a dimer similar to DB293 (46,49). The
SPR results suggest that the difference in inhibition
effects of DB1255 relative to other compounds such as
DB1998 is due to several factors. DB1255 is more
speciﬁc than DB1998 and should therefore have more
DB1255 molecules focused at speciﬁc sites and not lost
in non-speciﬁc binding. DB1255 also dissociates from
the speciﬁc site more slowly than DB1998 and this may
help in modulation of protein–DNA complexes and
function.
About the sequence-selective DNA recognition by
DB1255, we brought out the importance of the nucleo-
tides 50-(g)TT following the core 50-GGAA that showed
an AT-rich sequence interaction separated by a G base as
observed for other compounds (49). In parallel, studies on
ERG selective binding showed, as expected, the necessity
of the core 50-GGAA-30 for optimal ERG/DNA complex
formation. These results also showed the importance of
adjacent bases for binding, particularly the 50-GT di-
nucleotide following the core 50-GGAA (DNaseI foot-
printing and SPR, Figure 6).
Interestingly, such consensus binding site strictly correl-
ates with that deduced earlier by Wei et al. (16) from
ChIP-sequence analyses. This reinforces the therapeutic
interest in our compound with the objective to target
in vivo the strong and selective ERG/DNA binding sites
as deﬁned using ChIP-sequencing. At the cellular level, the
transient transfection assays conﬁrmed the gradual
decrease by DB1255 of ERG/DNA binding in the
cellular model using both a synthetic promoter model
and the OPN gene promoter (Figure 7).
As a transcriptional factor, ERG interacts with the
DNA to positively or negatively regulate target gene ex-
pression depending on the cell context. Thus, our selected
compound may positively or negatively interfere with the
transcription of ERG-controlled genes, but in a way that
may induce a change in the phenotype of ERG-dependent
cancers. However, DB1255 interacts with DNA on one
portion of the deﬁned ERG-binding site, suggesting that
it may not modulate all ERG-regulated genes but a
portion of those that include the proper DB1255 binding
site as deﬁned here (Figure 5C). Thus, further experiments
will be required to characterize the implication of
the ERG/DNA binding, modulated by the selected
compound regarding changes in gene expression.
Genome-wide analyses (ChIP-seq and transcriptome
analysis) in physiological conditions, disease conditions
and in presence of the DNA ligand would be of major
interest and could be compared with cells invalidated for
ERG expression using RNA interference. One part of the
question is provided by recent data of the invalidation of
ERG expression in the TMPRSS2-ERG positive VCaP
prostate cancer cell line evidencing the upregulation of
genes associated with differentiated luminal prostate
epithelial cells (50). In HUVEC endothelial cells, similar
transcriptome proﬁling evidenced the cytosolic histone-
deacetylase-6 gene (HDAC6) as a direct ERG transcrip-
tional target implicated in cell migration (51). The
vascular endothelial adhesion molecule VE-cadherin was
also described as a target for ERG, associated with angio-
genesis (52). Those genes and approaches would be of
major interest to validate the effect of ERG/DNA
binding inhibitory compounds such as DB1255.
In conclusion, we selected a di-(phenyl-thiophene-
amidine) compound as a DNA-binding modulator that
speciﬁcally targets the ERG/DNA complex. To our know-
ledge, this is the ﬁrst in cellulomodulationof theERG/DNA
binding by a small molecule targeting the protein/DNA
interaction. As a strong inhibitor, DB1255 thus offers a
therapeutic window for targeting ERG oncogenecity both
in leukaemia disease and in prostate cancer.
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Supplementary Figures 1–9.
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